Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections
摘要:
Novel siderophore-linked monobactams with in vitro and in vivo anti-microbial activity against MDR Gram-negative pathogens are described. (c) 2012 Published by Elsevier Ltd.
The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.
本发明涉及一类新的单环内酰胺衍生物及其用于治疗细菌感染的用途。
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections
作者:Mark J. Mitton-Fry、Joel T. Arcari、Matthew F. Brown、Jeffrey M. Casavant、Steven M. Finegan、Mark E. Flanagan、Hongying Gao、David M. George、Brian S. Gerstenberger、Seungil Han、Joel R. Hardink、Thomas M. Harris、Thuy Hoang、Michael D. Huband、Rebecca Irvine、Manjinder S. Lall、M. Megan Lemmon、Chao Li、Jian Lin、Sandra P. McCurdy、John P. Mueller、Lisa Mullins、Mark Niosi、Mark C. Noe、David Pattavina、Joseph Penzien、Mark S. Plummer、Hud Risley、Brandon P. Schuff、Veerabahu Shanmugasundaram、Jeremy T. Starr、Jianmin Sun、Jennifer Winton、Jennifer A. Young
DOI:10.1016/j.bmcl.2012.07.005
日期:2012.9
Novel siderophore-linked monobactams with in vitro and in vivo anti-microbial activity against MDR Gram-negative pathogens are described. (c) 2012 Published by Elsevier Ltd.